Core Insights - The company, Times Angel, reported strong growth in its mid-year performance for 2025, with a total case number for invisible orthodontics increasing by 47.7% year-on-year to approximately 225,800 cases, driven by both international and domestic markets [1][2] - Revenue increased by 33.1% year-on-year to approximately $161.4 million, with gross profit reaching $100.6 million and adjusted net profit at $19.5 million [1] - The company plans to strategically increase long-term investments in key areas to establish a more sustainable global business foundation [1][4] Group 1: Market Performance - In the international market, Times Angel achieved 117,200 cases, a year-on-year increase of 103.5%, benefiting from a low base last year and successful market expansion [2] - In the Chinese market, the case number reached 108,600, reflecting a year-on-year growth of 14%, driven by early intervention and emerging market strategies [2] - The company is enhancing public awareness of early intervention benefits for children's oral health, with a growing share of cases attributed to its KiD product line [2] Group 2: Innovation and R&D - Times Angel launched several innovative products and solutions for early treatment and complex cases, integrating key processes into the invisible orthodontics workflow [3] - The company is collaborating with universities for joint research, with results published in top international journals, providing solid academic support for innovation [3] - Intellectual property remains a core strategy, with ongoing investments in global patent layout and legal team strengthening to enhance compliance and innovation [3] Group 3: Operational Enhancements - The company is building a user-centered, environmentally friendly, and scalable world-class intelligent manufacturing system to meet growing market demands [3] - Significant resources are being allocated to upgrade data security infrastructure and operational processes to comply with data privacy regulations [4] - The CEO expressed confidence in the long-term growth prospects of the global invisible orthodontics industry, emphasizing investments in production scale, clinical service capabilities, and compliance [4]

Core Insights - The company, Times Angel, reported strong growth in its mid-year performance for 2025, with a total case number for invisible orthodontics increasing by 47.7% year-on-year to approximately 225,800 cases, driven by both international and Chinese markets [1][2] - Revenue increased by 33.1% year-on-year to approximately $161.4 million, with gross profit reaching $100.6 million and adjusted net profit at $19.5 million [1] - The company plans to strategically increase long-term investments in key areas to establish a more sustainable global business foundation [1][4] International Market Performance - In the international market, Times Angel achieved 117,200 cases, representing a year-on-year growth of 103.5%, attributed to a low base from the previous year and successful market expansion efforts [2] - The company expanded its market coverage through high-quality medical solution designs and continuous education programs led by key opinion leaders (KOLs) [2] Domestic Market Performance - In the Chinese market, the case number reached 108,600, with a year-on-year growth of 14%, driven by proactive early intervention strategies and emerging market developments [2] - The company focused on enhancing public awareness of early intervention benefits for children's oral health, with an increasing share of cases from its KiD children's product line [2] Product Innovation and R&D - Times Angel launched several innovative products and solutions for early treatment and complex cases, integrating key processes into the invisible orthodontics workflow [3] - The company is engaged in collaborative research with universities, with results published in top international journals, providing solid academic support for innovation [3] Intellectual Property and Compliance - Intellectual property remains a core strategy for Times Angel, with ongoing investments in global patent layout and legal team enhancement to strengthen compliance and innovation [3][4] - The company is committed to upgrading data security infrastructure to comply with data privacy regulations across all operational regions [4] Future Growth Strategy - The CEO expressed confidence in the long-term growth prospects of the global invisible orthodontics industry, emphasizing investments in production scale, clinical service capabilities, and compliance efforts to drive sustainable growth across all regions [4]

时代天使(06699.HK)发布公告，将于2025年9月30日派发截至2025年6月30日止6个月期间特别中期股息 每股0.46港元。 本文源自：金融界AI电报 ...

本文源自：金融界AI电报 时代天使(06699.HK)公布，于2025年8月25日，公司的全资附属公司无锡时代天使与上海马可菲斯及上 海马可菲斯现有股东订立投资协议，据此，无锡时代天使已有条件同意以现金代价人民币1000万元认购 上海马可菲斯经扩大注册股本的 5%。于投资完成后，该集团将实益拥有上海马可菲斯约9.7%股权的权 益。 ...

时代天使(06699.HK)公布2025年中期业绩，收入为1.614亿美元，同比增加33.1%。 毛利为约1亿美元， 同比增加32.9%。经调整净利润为1950万美元，同比增加84.8%。公司拥有人应占利润1464.3万美元，同 比增长362.65%;每股盈利0.09美元，特别中期股息每股股份0.46港元。 本文源自：金融界AI电报 ...

Core Viewpoint - Angelalign Technology (06699) has entered into an investment agreement to acquire a 5% stake in Shanghai Markofis for RMB 10 million, which will increase its total ownership to approximately 9.7% after the investment is completed [1] Group 1: Investment Details - The investment agreement was signed between Wuxi Angelalign, a wholly-owned subsidiary of Angelalign Technology, and Shanghai Markofis along with its existing shareholders [1] - The cash consideration for the investment is RMB 10 million [1] Group 2: Strategic Importance - Shanghai Markofis is recognized as a leading supplier of raw materials, components, and equipment in the invisible aligner industry [1] - The investment is deemed crucial for securing a reliable supplier of raw materials, which is essential due to the increasing demand for materials driven by the growth of the invisible aligner business [1] - The company believes that this investment will enhance collaboration with Shanghai Markofis, leading to synergistic benefits for its business development [1]

Core Viewpoint - The company, Times Angel (06699), has entered into an investment agreement to acquire a 5% stake in Shanghai Markofis for a cash consideration of RMB 10 million, which will result in an effective ownership of approximately 9.7% post-investment [1] Group 1: Investment Details - The investment agreement is between Wuxi Times Angel, a wholly-owned subsidiary of Times Angel, and Shanghai Markofis along with its existing shareholders [1] - The cash consideration for the investment is RMB 10 million [1] - Upon completion of the investment, Times Angel will hold approximately 9.7% equity interest in Shanghai Markofis [1] Group 2: Strategic Importance - Shanghai Markofis is recognized as a leading supplier of raw materials, components, and equipment in the invisible aligner industry [1] - The board believes that securing a reliable supplier of raw materials is crucial due to the increasing demand for materials driven by the growth of the invisible aligner business [1] - The investment is expected to strengthen the collaboration with Shanghai Markofis, leading to synergistic benefits for the company's business development [1]

时代天使(06699)发布公告，将于2025年9月30日派发截至2025年6月30日止6个月期间特别中期股息每股 0.46港元。 ...

2025年上半年，公司取得稳健业绩表现。达成案例数攀升、医学设计中心和隐形矫治器生产基地的高效 运营，共同推动收入、毛利及经营利润同比增长。公司报告期间的盈利表现也得益于为应对预期更加严 峻的关税环境而採取的严格的费用控制措施，包括：暂缓若干区域销售、营销、临床支持及客户服务等 方面的人员招募，以及延迟中国内地以外医学设计中心及生产基地的运营。报告期间，中国内地以外全 球市场案例数(其中包括AngelAligner品牌矫治器，Aditek品牌矫治器，以及为重要战略客户简单病例定 制的矫治器)增长迅速，这反映集团进入新市场并从低垂果实中获益所取得的初步成功。 时代天使(06699)公布2025年中期业绩，收入为1.614亿美元，同比增加33.1%。 毛利为约1亿美元，同比 增加32.9%。经调整净利润为1950万美元，同比增加84.8%。公司拥有人应占利润1464.3万美元，同比增 长362.65%;每股盈利0.09美元，特别中期股息每股股份0.46港元。 公司凭藉高质量的医学设计支持、稳定的交付，结合由关键意见领袖(KOLs) 主导的持续性教育培训以 及为重要战略客户简单病例定制的矫治器等方式，扩大在中国内地 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ANGELALIGN TECHNOLOGY INC. 時代天使科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6699） 修訂首次公開發售後受限制股份單位計劃 及首次公開發售後購股權計劃 茲提述本公司日期為2024年3月21日的公告及本公司日期為2024年4月23日的通 函，內容有關首次公開發售後受限制股份單位計劃及首次公開發售後購股權計劃。 董事會欣然宣佈，其已議決修訂首次公開發售後受限制股份單位計劃及首次公開 發售後購股權計劃如下： 修訂首次公開發售後受限制股份單位計劃 股東於2021年5月20日有條件批准及採納首次公開發售後受限制股份單位計劃， 並於2023年6月29日及2024年6月28日進行修訂。首次公開發售後受限制股份單 位計劃旨在認可承授人的貢獻，並提供激勵，以挽留彼等繼續投身於本集團的持 續營運及發展，及吸引適當人員促進本集團進一步發展。有關首次公開發售後受 限制股份單位計劃 ...